Canon Medical Partners With Surfacide to Provide Rapid Decontamination Solution for Imaging Systems

UV-C Decontamination Technology Can Decontaminate Imaging Equipment of Viral Infectious Diseases in Minutes

Hospitals and institutions are regularly using imaging as a frontline tool for triaging patients, and disinfection after use can be time-consuming when every second counts. To meet the need for fast decontamination, Canon Medical Systems USA, Inc. has partnered with Surfacide to offer Helios – a rapid decontamination tool for its imaging equipment.

The Surfacide Helios system provides an automated UV-C decontamination technology that significantly reduces bacteria, spores and viruses and is effective against a variety of advanced viral infectious diseases. Helios incorporates multiple automated UV-C emitters that work together to provide decontamination of the room in minutes to help improve workflow.

“At Canon Medical, our priority is to support our customers and their patients by providing them not only with innovative imaging systems, but also the latest technology advancements that can impact their outcomes and workflow,” said Satrajit Misra, vice president, Marketing and Strategic Development, Canon Medical Systems USA, Inc. “In the current healthcare climate, partnering with Surfacide to offer a solution that can quickly, easily and effectively decontaminate an imaging system can help hospitals and institutions manage their high throughput and keep patients safe by helping to prevent the spread of infection.”

“Today, two innovative technology leaders are focused on making imaging suites and hospitals safer for hospital healthcare workers and patients,” says Gunner Lyslo, Founder & CEO of Surfacide LLC. “Surfacide and Canon Medical are coming together at an urgent time when safety and infection prevention is paramount throughout the world. Surfacide and its multi-emitter UV-C technology will fight infectious diseases and decontaminate surfaces to create a much safer environment for patients and healthcare workers when it is needed the most.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”